4DMedical’s advanced lung imaging technology CT:VQ™ has been deployed at the Mayo Clinic, marking the sixth top US academic medical centre to adopt the system within seven months of FDA clearance.
- Mayo Clinic begins 90-day deployment of CT:VQ™ for ventilation and perfusion analysis
- Six leading US Academic Medical Centers now using CT:VQ™ since FDA clearance
- CT:VQ™ offers superior imaging without radioisotopes or contrast agents
- Mayo Clinic’s endorsement signals strong clinical validation and market potential
- Partnership with Philips supports broader commercial rollout
Mayo Clinic Joins Elite Group of CT:VQ™ Users
4DMedical Limited (ASX:4DX) has announced a significant milestone with the Mayo Clinic, the top-ranked hospital in the United States, initiating deployment of its CT:VQ™ technology. This marks the sixth prestigious US Academic Medical Center (AMC) to adopt the company’s breakthrough ventilation and perfusion imaging solution since FDA clearance in September 2025.
The initial 90-day deployment at Mayo Clinic is designed to integrate CT:VQ™ into clinical workflows and allow physicians to familiarise themselves with its advanced diagnostic capabilities. While not yet financially material, this step is strategically important, given Mayo Clinic’s global influence on clinical practice and technology adoption.
Rapid Institutional Adoption Reflects Clinical Value
Within just seven months of FDA approval, 4DMedical has secured deployments at Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, University of Miami, and now Mayo Clinic. This rapid uptake underscores the compelling advantages of CT:VQ™, which eliminates the need for radioactive tracers and contrast agents, delivers superior image resolution compared to traditional nuclear medicine, and integrates seamlessly into existing CT imaging workflows.
Such features not only enhance diagnostic precision but also open access to reimbursement pathways that support sustainable clinical adoption. The Mayo Clinic’s decision to trial CT:VQ™ sends a powerful signal to the broader US healthcare market about the technology’s readiness and transformative potential.
Strategic Partnerships and Future Growth
4DMedical’s partnership with Philips further strengthens its commercial position, enabling wider distribution and adoption of CT:VQ™. CEO Andreas Fouras highlighted the significance of Mayo Clinic’s endorsement, describing it as a landmark moment that validates the company’s technology and accelerates its ambition to establish CT:VQ™ as the new standard of care in ventilation-perfusion imaging.
With a growing sales pipeline and a network of elite reference sites, 4DMedical is well positioned to expand its footprint in the US and global markets. The company’s SaaS delivery model and integration of advanced AI capabilities continue to push the boundaries of respiratory imaging, promising earlier and more precise detection of lung diseases.
Looking Ahead
As Mayo Clinic clinicians build confidence in CT:VQ™ across pulmonary and cardiothoracic applications, the institution could become a pivotal reference site, catalysing broader commercial agreements and adoption. Investors and industry watchers will be keen to see how this deployment translates into full commercial terms and revenue growth in the coming months.
Bottom Line?
Mayo Clinic’s adoption of CT:VQ™ cements 4DMedical’s foothold in elite US healthcare, setting the stage for wider market penetration.
Questions in the middle?
- Will Mayo Clinic transition from the initial 90-day deployment to a full commercial agreement?
- How quickly will other US hospitals follow Mayo Clinic’s lead in adopting CT:VQ™?
- What impact will the Philips partnership have on accelerating CT:VQ™ sales and distribution?